EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche ...

Alys Pharmaceuticals is on the hunt for a large financing to carry forward its pipeline — an amalgamation of six Medicxi ...

GSK said it is holding steady in the face of ongoing regulatory and potential political pressures on its vaccines franchise, ...

Amgen's obesity drug AMG-513 on clinical hold; company reaffirms obesity market ambitions while advancing MariTide program ...

Novo Nordisk reports 26% sales growth in 2024, but projects lower 2025 growth of 16-24%. Full-year Wegovy sales up 86%, ...

Bristol Myers Squibb cuts 67 jobs in Lawrence Township, NJ, while Kyowa Kirin lays off 52 employees at Princeton facility, per NJ WARN notices.

China tensions, following US restrictions on Chinese rivals BGI and MGI. Illumina says China accounts for 7% of Q3 revenue.

Johnson & Johnson has asked a federal district court to expedite its decision in a case over the company’s proposed 340B ...

Despite uncertainty around HPV vaccine sales in China, Merck CEO Robert Davis said he’s confident the company can “deliver strong growth” and navigate Keytruda’s impending patent cliff.

Robert F. Kennedy Jr. advances toward Senate confirmation despite vaccine controversy, as key skeptic Sen. Bill Cassidy backs ...

Astellas is reorganizing its management team, and while it doesn't involve a change at the top as Daiichi Sankyo announced ...

At long last, the FDA approved Supernus Pharmaceuticals’ Parkinson’s disease treatment, which will be marketed as Onapgo.